Janus Henderson Group PLC Sells 1,660,724 Shares of Enliven Therapeutics, Inc. $ELVN

Janus Henderson Group PLC trimmed its position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 99.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 11,000 shares of the company’s stock after selling 1,660,724 shares during the quarter. Janus Henderson Group PLC’s holdings in Enliven Therapeutics were worth $431,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. KBC Group NV purchased a new stake in Enliven Therapeutics during the 1st quarter valued at $38,000. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Enliven Therapeutics by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock valued at $44,000 after acquiring an additional 594 shares during the period. BNP Paribas Financial Markets raised its stake in shares of Enliven Therapeutics by 33.3% during the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after acquiring an additional 930 shares during the last quarter. Los Angeles Capital Management LLC bought a new position in shares of Enliven Therapeutics during the fourth quarter valued at about $83,000. Finally, Quantbot Technologies LP boosted its holdings in shares of Enliven Therapeutics by 47.1% during the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after purchasing an additional 1,434 shares during the period. 95.08% of the stock is currently owned by institutional investors.

Insider Activity at Enliven Therapeutics

In other news, Director Lori Anne Kunkel sold 10,000 shares of the stock in a transaction on Friday, June 5th. The stock was sold at an average price of $34.54, for a total value of $345,400.00. Following the sale, the director directly owned 51,884 shares of the company’s stock, valued at approximately $1,792,073.36. This represents a 16.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mika K. Derynck sold 158,795 shares of the stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $60.21, for a total value of $9,561,046.95. Following the completion of the sale, the director directly owned 87,373 shares in the company, valued at approximately $5,260,728.33. This represents a 64.51% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 190,831 shares of company stock valued at $10,991,723 in the last 90 days. Corporate insiders own 3.00% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on ELVN. HC Wainwright boosted their price target on Enliven Therapeutics from $56.00 to $64.00 and gave the company a “buy” rating in a report on Thursday, July 9th. Mizuho increased their price objective on Enliven Therapeutics from $45.00 to $62.00 and gave the stock an “outperform” rating in a report on Tuesday, June 2nd. Guggenheim cut their price objective on Enliven Therapeutics from $80.00 to $78.00 and set a “buy” rating on the stock in a research report on Thursday. JonesTrading boosted their target price on Enliven Therapeutics from $45.00 to $70.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Friday, July 17th. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $72.67.

Enliven Therapeutics Price Performance

NASDAQ:ELVN opened at $59.42 on Tuesday. The firm has a market capitalization of $4.35 billion, a P/E ratio of -35.58 and a beta of 0.27. Enliven Therapeutics, Inc. has a one year low of $14.78 and a one year high of $62.32. The company’s 50-day simple moving average is $49.06 and its 200 day simple moving average is $40.00.

Enliven Therapeutics (NASDAQ:ELVN) last announced its earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). On average, equities research analysts expect that Enliven Therapeutics, Inc. will post -1.67 earnings per share for the current fiscal year.

Enliven Therapeutics Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.